205 related articles for article (PubMed ID: 3927867)
1. Pseudomonas bacteremia. Retrospective analysis of 410 episodes.
Bodey GP; Jadeja L; Elting L
Arch Intern Med; 1985 Sep; 145(9):1621-9. PubMed ID: 3927867
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
Kim HS; Park BK; Kim SK; Han SB; Lee JW; Lee DG; Chung NG; Cho B; Jeong DC; Kang JH
BMC Infect Dis; 2017 Jul; 17(1):500. PubMed ID: 28716109
[TBL] [Abstract][Full Text] [Related]
3. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: Retrospective analysis of 245 episodes.
Chatzinikolaou I; Abi-Said D; Bodey GP; Rolston KV; Tarrand JJ; Samonis G
Arch Intern Med; 2000 Feb; 160(4):501-9. PubMed ID: 10695690
[TBL] [Abstract][Full Text] [Related]
4. [Pseudomonas aeruginosa bacteremia associated with hematologic disorders [III]. Prognostic factors].
Funada H; Machi T; Matsuda T
Kansenshogaku Zasshi; 1989 Aug; 63(8):880-5. PubMed ID: 2507688
[TBL] [Abstract][Full Text] [Related]
5. Serratia bacteremia: review of 118 cases.
Saito H; Elting L; Bodey GP; Berkey P
Rev Infect Dis; 1989; 11(6):912-20. PubMed ID: 2602776
[TBL] [Abstract][Full Text] [Related]
6. Pseudomonas aeruginosa bacteraemia. Is pancreatobiliary disease a risk factor?
Chen SC; Lawrence RH; Byth K; Sorrell TC
Med J Aust; 1993 Nov; 159(9):592-7. PubMed ID: 8232033
[TBL] [Abstract][Full Text] [Related]
7. Review of Citrobacter bacteremia in cancer patients over a sixteen-year period.
Samonis G; Anaissie E; Elting L; Bodey GP
Eur J Clin Microbiol Infect Dis; 1991 Jun; 10(6):479-85. PubMed ID: 1915382
[TBL] [Abstract][Full Text] [Related]
8. Pseudomonas aeruginosa septicemia in childhood cancer patients.
Jackson MA; Wong KY; Lampkin B
Pediatr Infect Dis; 1982; 1(4):239-41. PubMed ID: 7177913
[TBL] [Abstract][Full Text] [Related]
9. β-Lactam plus aminoglycoside or fluoroquinolone combination versus β-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis.
Vardakas KZ; Tansarli GS; Bliziotis IA; Falagas ME
Int J Antimicrob Agents; 2013 Apr; 41(4):301-10. PubMed ID: 23410791
[TBL] [Abstract][Full Text] [Related]
10. Occurrence of antipseudomonal beta-lactams and aminoglycosides resistance in Pseudomonas aeruginosa during therapy.
Pagani L; Scarabelli M; Cereda PM; Debiaggi M
Microbiologica; 1987 Jan; 10(1):103-10. PubMed ID: 3106759
[TBL] [Abstract][Full Text] [Related]
11. [Pseudomonas aeruginosa bacteremia associated with hematologic disorders [II]. Blood culture isolates and surveillance cultures].
Funada H; Machi T; Matsuda T
Kansenshogaku Zasshi; 1989 Aug; 63(8):874-9. PubMed ID: 2507687
[TBL] [Abstract][Full Text] [Related]
12. Comparative review of combination therapy: two beta-lactams versus beta-lactam plus aminoglycoside.
DeJace P; Klastersky J
Am J Med; 1986 Jun; 80(6B):29-38. PubMed ID: 3524218
[TBL] [Abstract][Full Text] [Related]
13. Community-acquired Pseudomonas aeruginosa sepsis in previously healthy infants and children: analysis of forty-three episodes.
Huang YC; Lin TY; Wang CH
Pediatr Infect Dis J; 2002 Nov; 21(11):1049-52. PubMed ID: 12442028
[TBL] [Abstract][Full Text] [Related]
14. Development of a combination antibiogram for Pseudomonas aeruginosa bacteremia in an oncology population.
Smith ZR; Tajchman SK; Dee BM; Bruno JJ; Qiao W; Tverdek FP
J Oncol Pharm Pract; 2016 Jun; 22(3):409-15. PubMed ID: 25956419
[TBL] [Abstract][Full Text] [Related]
15. Addition of rifampin to combination antibiotic therapy for Pseudomonas aeruginosa bacteremia: prospective trial using the Zelen protocol.
Korvick JA; Peacock JE; Muder RR; Wheeler RR; Yu VL
Antimicrob Agents Chemother; 1992 Mar; 36(3):620-5. PubMed ID: 1622173
[TBL] [Abstract][Full Text] [Related]
16. Pseudomonas spp. complications in patients with HIV disease: an eight-year clinical and microbiological survey.
Manfredi R; Nanetti A; Ferri M; Chiodo F
Eur J Epidemiol; 2000 Feb; 16(2):111-8. PubMed ID: 10845259
[TBL] [Abstract][Full Text] [Related]
17. Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas aeruginosa bacteremia.
Bliziotis IA; Petrosillo N; Michalopoulos A; Samonis G; Falagas ME
PLoS One; 2011; 6(10):e26470. PubMed ID: 22046290
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of empiric aminoglycoside monotherapy for Pseudomonas aeruginosa bacteremia.
Phe K; Bowers DR; Babic JT; Tam VH
Diagn Microbiol Infect Dis; 2019 Apr; 93(4):346-348. PubMed ID: 30522794
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of antipseudomonal antimicrobic agents.
Gilbert DN
Antibiot Chemother (1971); 1985; 36():111-33. PubMed ID: 3923909
[TBL] [Abstract][Full Text] [Related]
20. Pseudomonas aeruginosa bacteremia: univariate and multivariate analyses of factors influencing the prognosis in 133 episodes.
Bisbe J; Gatell JM; Puig J; Mallolas J; Martinez JA; Jimenez de Anta MT; Soriano E
Rev Infect Dis; 1988; 10(3):629-35. PubMed ID: 3393785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
